Pediatric Cancer News
Early radiotherapy may preserve visual acuity for certain children with sporadic optic pathway/hypothalamic gliomas.
In an international, multicenter collaboration, experts modified the RECIST criteria for use as objective endpoints in clinical trials of retinoblastoma therapies.
Researchers found that the therapy did not improve EFS or OS in high-risk patients and also led to an increase in toxic side effects.
Investigators sought to assess outcomes following CD19 CAR T-cell therapy in children and young adults who underwent alloHSCT for B-cell acute lymphoblastic leukemia.
Investigators conducted a study to determine the incidence and clinical course of BK virus hemorrhagic cystitis in children undergoing hematopoietic cell transplantation.
After a cancer diagnosis, male adolescents may be unprepared to make decisions about fertility preservation independently and instead need parental involvement.
Researchers hope their findings could lead to targeted interventions to improve cognitive outcomes in pediatric brain tumor survivors from families with low socioeconomic status.
A multicenter, randomized, phase 3 trial compared blinatumomab with intensive multidrug consolidation chemotherapy in children with high-risk, first-relapse B-cell ALL.
Although the number of reported cases of SARS-CoV-2 infection among pediatric patients with cancer has been low, the effect of the pandemic on cancer care services for this population is not well understood.
New NCCN guidelines for Wilms tumor contain up-to-date information on screening, diagnosis, risk stratification, and treatment for this rare childhood renal cancer.
Diabetes and metabolic syndrome represent two of the most common long-term complications in survivors of childhood cancer.
Ruxolitinib, a selective nonreceptor Janus kinase 1/2 inhibitor shown to have activity in adults with refractory GVHD, was studied in pediatric patients.
An evaluation of a large dataset sought to determine use of imaging studies in children treated in children’s hospital emergency departments.
Photobiomodulation shows impressive results in pretrial use for treatment and prevention of treatment-associated mucositis in pediatric patients.
Investigators assessed the frequency, fusion partners, and clinical course in pediatric patients with NTRK fusion–positive tumors.
Population-based study evaluated survival outcomes for patients with cancer diagnosed over a 41-year period.
Cancer incidence trends across 41 countries demonstrated sharp increases and decreases in certain cancer types over the last 15 years.
Survival from time of recurrence was similar to that seen in younger patients.
Pediatric medulloblastoma demonstrated a distinct methylation profile that could identify the disease and monitor treatment response.
As part of the Zero Childhood Cancer Program, high-risk pediatric tumors were characterized by whole-genome sequencing, RNA sequencing, and methylation profiling.